<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127373">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444040</url>
  </required_header>
  <id_info>
    <org_study_id>GCF-027</org_study_id>
    <nct_id>NCT01444040</nct_id>
  </id_info>
  <brief_title>Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost</brief_title>
  <official_title>A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the intraocular pressure (IOP) lowering effect of two iStent inject devices
      versus medical therapy in eyes of subjects with primary open-angle glaucoma,
      pseudoexfoliative glaucoma, or ocular hypertension naïve to medical and surgical therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the intraocular pressure (IOP) lowering effect of two iStent inject devices
      versus medical therapy in eyes of subjects with primary open-angle glaucoma,
      pseudoexfoliative glaucoma, or ocular hypertension naïve to medical and surgical therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from screening in mean diurnal IOP (mm Hg) at the Month 12 visit.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean diurnal IOP vs. screening</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in screening in time-wise IOPs</measure>
    <time_frame>Various Month 12-60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders</measure>
    <time_frame>Various 12-60 months</time_frame>
    <description>A responder is defined as a subject with a certain target IOP value or a certain reduction of IOP as compared to screening. In the iStent inject group, a responder must not be on an ocular hypotensive medications or have had a postoperative procedure to reposition or remove stent(s) prior to the visit. Due to the lack of a complete consensus on the definition of a clinical responder, a set of target IOP values (e.g., downwards from 22 mm Hg in steps of 1 mm Hg) and reductions of IOP (e.g., downwards from the highest reduction in IOP in steps of 5%) will be evaluated.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse event reporting</measure>
    <time_frame>0-60 months</time_frame>
    <description>Rate of ocular adverse events through 60 months
Findings from IOP, best corrected visual acuity, visual field
Findings from slit-lamp, fundus and gonioscopic examinations</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>iStent inject</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of two iStent inject devices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Travoprost drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent inject</intervention_name>
    <description>Implantation of two iStent inject devices</description>
    <arm_group_label>iStent inject</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost</intervention_name>
    <description>Travoprost drops</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phakic study eye

          -  IOP ≥ 21 mmHg and ≤ 40 mmHg at the screening visit (subjects with OHT require a
             second screening IOP measurement

        Exclusion Criteria:

          -  Aphakic or pseudophakic eyes (AC-IOLs or PC-IOLs)

          -  Previous usage of topical prostaglandin analogues or prior medical therapy for
             glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilit A Voskanyan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.V. Malayan Ophthalmological Center, Yerevan, Armenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeff Wells, PharmD, MBA</last_name>
    <phone>949-367-9600</phone>
    <email>jwells@glaukos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Ellen Giamporcaro, MS</last_name>
    <phone>949-367-9600</phone>
    <phone_ext>247</phone_ext>
    <email>jegiamporcaro@glaukos.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S.V. Malayan Ophthalmological Center</name>
      <address>
        <city>Yerevan</city>
        <zip>0001</zip>
        <country>Armenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leon Au, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Imran Masood, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerd Auffarth, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iqbal Ahmed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Vold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anslem Juenemann, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manfred Tetz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Belda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amadeu Carceller Guillamet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Fea, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>L. Jay Katz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M Kahook, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Liebmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Martinez de la Casa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yana Oganova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vahan Papoyan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Levon Nersisyan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Armenia</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 18, 2015</lastchanged_date>
  <firstreceived_date>September 28, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open angle glaucoma</keyword>
  <keyword>POAG</keyword>
  <keyword>Ocular hypertension</keyword>
  <keyword>Pseudoexfoliative glaucoma</keyword>
  <keyword>Naïve to treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
